EFFECTS OF TIBOLONE ON LIPOPROTEIN(A) AND HDL SUBFRACTIONS

被引:39
作者
FARISH, E [1 ]
BARNES, JF [1 ]
ROLTON, HA [1 ]
SPOWART, K [1 ]
FLETCHER, CD [1 ]
HART, DM [1 ]
机构
[1] STOBHILL GEN HOSP,DEPT GYNAECOL,GLASGOW G21,LANARK,SCOTLAND
关键词
LIPOPROTEIN(A); HDL SUBFRACTIONS; TIBOLONE; MENOPAUSE; LIPIDS;
D O I
10.1016/0378-5122(94)90019-1
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective: To determine the effects of tibolone, a synthetic steroid used to alleviate climacteric symptoms and prevent osteoporosis, on lipoprotein metabolism, with particular reference to lipoprotein(a) levels and HDL subfraction profiles. Design: Thirty nine postmenopausal women were treated with tibolone (Livial) 2.5 mg/day for 6 months and fasting serum lipoprotein levels were estimated at 0, 2, 4 and 6 months. Results. Lipoprotein(rt) levels were reduced significantly over the 6 months from a median level of 245 (range <60-780) mg/l to 152 (range < 60-530) mg/l, a reduction of 39% in the median level. A decrease was observed in approximately two thirds of the women. Reductions were noted in all 6 subjects whose pretreatment levels were high, although concentrations remained at a level associated with increased risk in all but one. There were significant decreases in triglycerides and VLDL cholesterol and no significant change in LDL cholesterol. There was a significant reduction of 18% in HDL cholesterol and a 26% reduction in the HDL(2):HDL(3) ratio. Conclusion: The reduction in lipoprotein(a) levels may have a beneficial effect on cardiovascular risk, which could go some way towards balancing the potentially adverse effect on the cardiovascular system caused by the reduction in HDL cholesterol.
引用
收藏
页码:215 / 219
页数:5
相关论文
共 27 条
  • [1] REDUCTION OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE, APOLIPOPROTEIN D AND THE LP(A) LIPOPROTEIN WITH THE ANABOLIC-STEROID STANOZOLOL
    ALBERS, JJ
    TAGGART, HM
    APPLEBAUMBOWDEN, D
    HAFFNER, S
    CHESNUT, CH
    HAZZARD, WR
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1984, 795 (02) : 293 - 296
  • [2] BENEDEKJASZMANN LJ, 1987, MATURITAS S, V1, P25
  • [3] A DOUBLE-BLIND CROSSOVER STUDY ON THE EFFECTS OF ORG OD14 COMPARED TO ESTRADIOL VALERATE AND PLACEBO ON LIPID AND CARBOHYDRATE-METABOLISM IN OOPHORECTOMIZED WOMEN
    CRONA, N
    SILFVERSTOLPE, G
    SAMSIOE, G
    [J]. ACTA ENDOCRINOLOGICA, 1983, 102 (03): : 451 - 455
  • [4] DAVID JA, 1986, CLIN CHEM, V32, P1094
  • [5] DEALOYSIO D, 1987, MATURITAS S, V1, P49
  • [6] A MICROMETHOD FOR THE RAPID ULTRA-CENTRIFUGAL SEPARATION OF HUMAN-PLASMA HIGH-DENSITY LIPOPROTEIN SUBFRACTIONS, HDL2 AND HDL3
    EYRE, J
    HAMMETT, F
    MILLER, NE
    [J]. CLINICA CHIMICA ACTA, 1981, 114 (2-3) : 225 - 231
  • [7] LIPOPROTEIN (A) CONCENTRATIONS IN POSTMENOPAUSAL WOMEN TAKING NORETHISTERONE
    FARISH, E
    ROLTON, HA
    BARNES, JF
    HART, DM
    [J]. BRITISH MEDICAL JOURNAL, 1991, 303 (6804) : 694 - 694
  • [8] EFFECTS OF TREATMENT WITH ESTRADIOL LEVONORGESTREL ON BONE, LIPOPROTEINS AND HORMONE STATUS IN POSTMENOPAUSAL WOMEN
    FARISH, E
    HART, DM
    GRAY, CE
    BEASTALL, G
    FLETCHER, CD
    LINDSAY, R
    [J]. CLINICAL ENDOCRINOLOGY, 1989, 31 (05) : 607 - 615
  • [9] THE EFFECTS OF CONJUGATED EQUINE ESTROGENS WITH AND WITHOUT A CYCLICAL PROGESTOGEN ON LIPOPROTEINS, AND HDL SUBFRACTIONS IN POSTMENOPAUSAL WOMEN
    FARISH, E
    FLETCHER, CD
    HART, DM
    TEO, HTHTC
    ALAZZAWI, F
    HOWIE, C
    [J]. ACTA ENDOCRINOLOGICA, 1986, 113 (01): : 123 - 127
  • [10] FARISH E, 1986, CLIN CHIM ACTA, V159, P147